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Diabetes mellitus (DM) is a pandemic disease and an important cardiovascular (CV) risk
factor. The atherogenic dyslipidemia in diabetes (ADD) is characterized by high serum
triglycerides, high small dense LDL levels, low HDL levels and postprandial lipemia. Insulin
resistance is a primary cause for ADD. Though statins are highly effective for CVD pre-
vention in DM but a significant residual CV risk remains even after optimal statin therapy.
Fibrates, niacin and omega-3 fatty acids are used in addition to statin for treatment of ADD
(specifically hypertriglyceridemia). All these drugs have some limitations and they are far
from being ideal companions of statins. Many newer drugs are in pipeline for management
of ADD. Dual PPAR a/g agonists are in most advanced stage of clinical development and
they have a rational approach as they control blood glucose levels (by reducing insulin
resistance, a primary factor for ADD) in addition to modulating ADD. Availability of dual
PPAR a/g agnosits and other drugs for ADD management may improve CV outcomes and
decrease morbidity and mortality in diabetic patients in future.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction millions.1 Being a highly populated country, India also has aDiabetes mellitus (DM) is a global epidemic and important
cause of morbidity and mortality. As per International Dia-
betes Federation (IDF) estimate, 366 million people worldwide
had DM in 2011; by 2030, this number will increase to 552H.K. Chopra).
2013, Cardiological Societlarge population suffering from DM. The Indian Council of
Medical ResearcheIndia Diabetes (ICMReINDIAB) study had
extrapolated its phase I results in 2011, which estimates 62.4
million individuals with diabetes and 77.2 million with pre-
diabetes in India.2y of India. All rights reserved.
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diovascular disease (CVD) risk factors and even considered as
an equivalent to myocardial infarction.3 Dyslipidemia is also
considered as very important CVD risk factor. Most of diabetic
patients have some kind of dyslipidemia. As per an Indian
study, 85.5% of men and 97.8% of women in India with type 2
diabetes mellitus (T2DM) have concomitant dyslipidemia.4
Presence of T2DM and dyslipidemia both increase the CV
risk by 3e4 times compared to non-diabetic patients with
dyslipidemia.5 Statins are very commonly used in diabetic
patients and they reduce CVD risk by 20e30%.6,7 The residual
CVD risk (70e80%) can be due to other risk factors like
sedentary lifestyle, smoking, hypertension, psychological
stress, atherogenic dyslipidemia, low HDL levels, etc.
Addressing these risk factors is important for the further
reduction of CVD risk in diabetic patients.2. Atherogenic dyslipidemia in diabetes
(ADD)
The most common pattern of dyslipidemia in type 2 diabetic
patients is atherogenic dyslipidemiawhich is characterized by
elevated triglycerides (TGs), raised small dense LDL (sdLDL)
levels and decreased HDL cholesterol levels.8
In 1990, Austin et al first described a risk-conferring lipid/
lipoprotein profile, termed ‘‘atherogenic dyslipidemia’’ or the
‘‘atherogenic lipoprotein phenotype’’ that comprises a higher
proportion of sdLDL particles, reduced HDL-C, and increased
TGs.9 Atherogenic dyslipidemia is characteristically seen in
patients with obesity, the metabolic syndrome, insulin resis-
tance, and T2DM10,11 and has emerged as an important
marker for the increased CVD risk observed in these
populations.
As shown in Fig. 1, Insulin resistance (IR) is primarily
responsible for the development of ADD in T2DM. IR at the
adipocyte results in increased release of free fatty acids (FFA)
into the circulation. A similar accumulation of fatty acids
could arise from defects in fatty acid transporters or intra-
cellular binding proteins. Increased FFA flux to the liver
stimulates the assembly and secretion of very low densityFig. 1 e Pathogenesis of ADD (IR, insulin resistance; CE, cholest
triglycerides, Apo B: apolipoprotein B, VLDL: very low density lip
HDL: high density lipoproteins, Apo A: apolipoprotein A).lipoprotein (VLDL) resulting in hypertriglyceridemia. In addi-
tion, VLDL stimulates the exchange of cholesteryl esters from
both HDL and LDL for VLDL TG. Apo AI can dissociate fromTG-
enriched HDL. This free Apo AI is cleared rapidly from plasma,
in part by excretion through the kidney, thus reducing the
availability of HDL for reverse cholesterol transport. TG-
enriched LDL can undergo lipolysis and become smaller and
denser. Low levels of HDL and the presence of small dense LDL
are each independent risk factors for cardiovascular disease.12
Thus, hypertriglyceridemia is the initial lipid abnormalities
leading to others in ADD. Various studies have shown high
prevalence of hypertriglyceridemia in T2DM. In a prescription
audit in UK on 14652 diabetic patients who are already on
statin therapy, 46.3% of patients have hypertriglyceridemia
(TG >150 mg/dl).13 In a cross sectional study in 702 diabetic
patients, 83% of patients had hypertriglyceridemia.14 In the
11-year follow-up of the Paris Prospective Study, hyper-
triglyceridemia (but not hypercholesterolemia) predicted CHD
mortality in a combined group of subjects with impaired
glucose tolerance and diabetes.15
Addressing the hypertriglyceridemia can reduce the
further lipid abnormalities in T2DM patients. Here we discuss
the pathogenesis andmanagement of hypertriglyceridemia in
ADD.3. Hypertriglyceridemia in ADD and
atherosclerosis
Consequences of hypertriglyceridemia in ADD which pro-
motes atherosclerosis are mentioned in Table 1. TGs, repre-
sents an important biomarker of CVD risk because of their
associationwith atherogenic remnant particles and Apo CIII, a
proinflammatory, proatherogenic protein found on all classes
of the plasma lipoproteins. Several species of triglyceride-rich
lipoproteins (TRLs) including VLDL and VLDL remnants, as
well as chylomicron (CM) remnants appear to promote
atherogenesis independently of LDL. Remnant species result
from partial hydrolysis by lipoprotein lipase (LPL) of TRLs of
hepatic and intestinal origin that have picked up cholesterol
esters from HDL through the action of cholesterol estereryl ester, CETP: cholesterol ester transport protein, TG:
oprotein, FFA: free fatty acids, LDL: low density lipoproteins
Table 1 e Consequences of hypertriglyceridemia.16
Low levels of HDL-C
The presence of small, dense LDL particles
The presence of atherogenic triglyceride-rich
lipoprotein remnants
Insulin resistance
Increases in coagulability and viscosity
Proinflammatory status
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 6 8 3e6 9 0 685transfer protein (CETP).17 Similar to oxidized LDL, these
cholesterol enriched, TG-poor species are subject to endo-
thelial accumulation and uptake by macrophages to form
foam cells.18 Foam cells promote fatty streak formation, the
precursor of atherosclerotic plaque.
To avoid the atherogenic inflammatory process, TRL rem-
nants must be cleared from plasma and metabolized by the
liver before endothelial accumulation occurs. However,
hypertriglyceridemic states are associated with increased
VLDL production and delayed VLDL clearance from circula-
tion.19 High liver secretion of large TG-rich VLDL that contains
Apo CIII is a common finding in hypertriglyceridemia and in
some cases has been associated with IR.20 In addition, delayed
clearance of all Apo B lipoproteins, including VLDL, has been
attributed to different mechanisms such as Apo CIII e medi-
ated inhibition of Apo E and Apo B-100 binding to hepatic re-
ceptors and proteoglycan; reduced activity of LPL, hepatic TG
lipase, or novel receptors such as GPI anchored HDL-binding
protein 1 (GPIHBP1) or proteoglycan; and finally, reduced Apo.
E and Apo E to CIII ratio reflecting reduced ability of the
lipoproteins to be taken up by the liver. Similarly, CMs are
taken up by the liver via LDL receptors or LDL receptor-related
proteins and unless their TG core is removed they are not
considered atherogenic due to their very large size, which
slows entry into the arterial intima. It is the resulting CM
remnants that are atherogenic, presumably because they are
sufficiently small to pass through the endothelial cell barrier
to the arterial intima.4. Hypertriglyceridemia and CV risk
Individual epidemiologic studies have shown variable results
regarding the strength of association between hyper-
triglyceridemia and CHD, specifically after adjusting for the
presence of associated risk factors such as insulin resistance
and low HDL-C levels which are components of ADD.21
Therefore, meta-analysis has been crucial to distinguish
hypertriglyceridemia as an independent risk factor from a risk
marker of associated conditions such as those in the meta-
bolic syndrome.
In 2007, Sarwar et al22 performed a large meta-analysis of
29 prospective studies from Western populations and re-
ported an odds ratio of 1.7 (70% increased risk) comparing the
risk of CHD for those in the upper to lower tertiles of the TG
distribution after adjusting for other risk factors. This study
found no difference between men and women in the strength
of association. A similar odds ratio (1.7) was reported in a
meta-analysis that included data from 26 prospective studiesin Asian and Pacific populations irrespective of ethnicity, age
and sex.235. Current therapies for
hypertriglyceridemia in diabetes
Various drug therapies available for hypertriglyceridemia are
used in diabetic patients to control high TGs.6. Non-pharmacological management
Nutritionmeasurements that affect serum triglycerides levels
include body weight status; body fat distribution; weight loss;
the macronutrient profile of the diet, including type and
amount of dietary carbohydrate, fat and alcohol consumption.
Importantly, multiple interventions can yield additive tri-
glyceride-lowering effects that can result in significant re-
ductions in triglyceride levels.
A weight loss of 5%e10% results in a 20% decrease in tri-
glycerides, approximately a 15% reduction in LDL-C, and an
8%e10% increase in HDL-C.24 Meta-analyses have reported
that for every 1 kg of weight loss, triglyceride levels decrease
1.9%, or 1.5 mg/dL.25
In a meta-analysis, a moderate-fat diet (32.5%e50% of cal-
ories from fat) versus a lower-fat diet (18%e30% of calories
from fat) resulted in a decrease in triglyceride level of 9.4 mg/
dL (P < 0.00001) in those without T2DM. However, in those
with T2DM, the moderate-fat diet resulted in greater triglyc-
eride reduction (24.8 mg/dL, P < 0.05) than seen with the low-
fat diet.26
Alcohol abusemay be associated with hypertriglyceridemia;
nearly 1 in 5 hospitalized alcoholics have triglyceride levels
exceeding 250 mg/dL.27 Therefore, in subjects with very
high triglyceride levels, complete abstinence is strongly
recommended.28
In a study of 2906 middle aged men, moderately intensive
activity (i.e., jogging 10 miles weekly) versus no activity was
associated with a 20% lower fasting triglyceride level; the
highest activity level (20 miles weekly) was also accompanied
by the lowest mean fasting triglyceride level (86 mg/dL).297. Pharmacological treatment of
hypertriglyceridemia
7.1. Statins
Statins are widely used for lipid lowering as well as CVD risk
management. In diabetes, statins are indicated for all patients
of CVD and primary prevention of CVD in patients > 40 years
with one other CV risk factor (hypertension, albuminuria, etc)
irrespective of lipid profile.30 Statins also lower TG levels and
increase HDL modestly.31 Trials of statin monotherapy found
that increased baseline TG levels predicted worse CVD out-
comes32,33 and that statins reduced CVD better in patients
who had high baseline TGs.34 This provides a rationale
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 8 3e6 9 0686for statin therapy in patients with mild to moderate
hypertriglyceridemia.
7.2. Fibrates
Fibrates modulate the activity of nuclear receptor PPAR
(peroxisome proliferator-activated receptor)-alpha, resulting
in increased lipoprotein lipase activity (causing catabolism of
TGs in VLDL and chylomicrons), reduced secretion of VLDL,
inhibition of Apo CIII expression, and increased production of
apolipoproteins Apo AI and Apo AII. Fibrates reduce TGs by
30%e60% and increase HDL by 5%e15%.35 The effect of
fibrates on LDL-C levels are varied. In patients with marked
hypertriglyceridemia, LDL-C may be unchanged or substan-
tially increased,36 whereas fibrates usually reduce LDL-C (5%e
20%) in individuals with elevated LDL-C and less severe
hypertriglyceridemia. In addition, fibrates may reduce the
number of small, more dense LDL particles.37
In the Veterans Affairs HDL Intervention Trial (VAHIT),
men with a history of CHD who had low HDL-C (mean of
32 mg/dL) and low LDL-C (mean of 111 mg/dL) were treated
with gemfibrozil (n: 1264) or matching placebo (n:1267) and
followed for 5 years.38 In the overall population, gemfibrozil
significantly reduced the risk of a CHD event versus placebo by
22% (P ¼ 0.006), and in the subgroup with TG >150 mg/dL the
risk reduction was 27% (P < 0.01). The risk reduction with
gemfibrozil was greater with increasing tertiles of baseline TG
concentrations.
Although results of the individual trials varied for their
primary outcomes, post hoc analysis of these trials and a
meta-analysis showed that the relative risk reduction for CVD
events was statistically significant in patients with athero-
genic dyslipidemia (high TGs and/or low HDL-C).39,40 In
Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) study, 9795 T2DM patients were randomized to feno-
fibrate or placebo. The follow-up was for 5 years. In the initial
analysis, it was observed that fenofibrate did not reduce CVD
events in overall population (Hazard ratio [HR] 0$89, 95% CI
0$75e1$05; p ¼ 0$16). While it reduced CVD events by 23% in
subgroup of patients who had baseline TG > 200 mg/dl.41
These results suggests that CV protective effects of fenofi-
brate is seen in ADD patients with hypertriglyceridemia,
specially when TG > 200 mg/dl. Similarly a meta-analysis of 5
large studies, including 4726 patients on fibrates have shown
that fibrate therapy reduce CV events by 35% in patients with
TG >204 mg/dl and HDL <34 mg/dl.
In the lipid arm of the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) trial, the use of fenofibrate plus
simvastatin versus simvastatin alone was examined in 5518
patients with type 2 diabetes mellitus who were at high risk
for cardiovascular disease.42 Fenofibrate reduced TG levels
versus placebo but did not significantly reduce the primary
CHD outcome, the first occurrence of nonfatal myocardial
infarction, nonfatal stroke, or death from cardiovascular
causes (HR 0.92; P 5.32) over the mean follow-up of 4.7 years.
In subgroup analysis of patients with baseline TGs in the
highest tertile (>204 mg/dL) and baseline HDL-C below
the lowest third (<34 mg/dL), the percent reduction in
the primary cardiovascular disease end point was 31%
(p < 0.03).43Though fibrates are far from ideal drugs to manage ADD. It
is well-known that they can increase the serum LDL levels
significantly in patients with very high TGs (>500 mg/dl) due
to increased LDL production from VLDL. This can be harmful
for ADD patients where management of LDL is the primary
objective in dyslipidemia management. Fibrates are also
known toworsen the renal functions especially when patients
has established chronic kidney disease (CKD). Diabetes is
most common cause of CKD.44 They also increases the risk of
muscle related adverse events specifically rhabdomyolysis.457.3. Niacin
Niacin at doses up to 3 g/d can lower plasmaTG levels by 30%e
50%, increase levels of HDL-C by 20%e30% and reduce LDL-C
by 5%e25%.46 The mechanisms of action of niacin are com-
plex and include inhibition of hepatocyte diacylglycerol
acyltransferase-2, a key enzyme for TG synthesis; accelerated
intracellular hepatic Apo B degradation; decreased secretion
of VLDL and LDL particles; impairment of the hepatic catab-
olism of Apo AI (versus Apo AII), which increases HDL half-life
and concentrations of Apo AI-containing HDL subfractions;
and inhibition of the removal of HDL-Apo AI. Niacin may also
increase the vascular endothelial cell reductioneoxidation
state, resulting in the inhibition of oxidative stress and
vascular inflammatory genes, key cytokines involved in
atherosclerosis. Although niacin may decrease free fatty acid
mobilization from adipose tissue via the G protein e coupled
receptor, this pathway may be only a minor factor in
explaining the lipid effects of niacin.47
Use of niacin in ADD is difficult as it is known to increase
blood glucose and worsen glycemic control. Niacin has also
failed to provide cardiovascular benefits in recent studies
where patients were already on statin therapy. In the AIM-
HIGH trial, investigators examined the effects of high-dose
extended release niacin added to statin therapy in 3414 pa-
tients with heart and vascular disease and with low HDL-C
and elevated TG. One third patients in this study had dia-
betes mellitus at the baseline. However, results from a pre-
planned interim analysis suggested a lack of efficacy for
niacin, and, in those treated with niacin versus placebo, a
slightly greater rate of ischemic stroke. Therefore, the study
was stopped after a mean follow-up of 3 years.487.4. Omega-3 fatty acids
Omega-3 fatty acids, mainly docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) reduce TG by approximately
20%e55% and lower TG-rich lipoproteins.49 EPA and DHA
doses of at least 2 g/day are required for significant lipid
effects.50
Omega-3 fatty acids reduce hepatic secretion of TG-rich
VLDL particles, reduce the TG content of secreted VLDL par-
ticles, and increase TG clearance from the blood by lowering
the concentration of Apo CIII, an inhibitor of lipoprotein lipase
activity.51 In addition, omega-3 fatty acids containing EPA and
DHA increase the rate of conversion of VLDL to LDL particles
and reduce the exchange of TG for cholesteryl esters in cir-
culation, which may produce an increase in plasma LDL-C
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 6 8 3e6 9 0 687levels. However, the overall number of atherogenic particles is
typically not increased.52
In JELIS (Japan EPA Lipid Intervention Study),53 18645 pa-
tients (16% of which were diabetics) with dyslipidemia were
randomized to 1.8 g/day EPA or placebo for 4.6 years. The
baseline lipid profile was as following: serum TG: 155 mg/dl,
LDL: 188 mg/dl, HDL: 60 mg/dl, total cholesterol: 277 mg/dl.
The primary endpoint was any major coronary event,
including sudden cardiac death, fatal and nonfatalmyocardial
infarction, and other nonfatal events including unstable
angina pectoris, angioplasty, stenting, or coronary artery
bypass grafting. At the end of study, a significant 19% risk
reduction in primary end point was noticed in patients in EPA
group. However, no significant difference in primary endpoint
was seen in diabetic subgroup.
In GISSI (Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto miocardico) e Prevenzione study, 11,324 patients
surviving recent (<3 months) myocardial infarction (15%were
diabetics at baseline) were randomly assigned supplements of
n-3 PUFA (882 mg EPA/DHA daily), vitamin E (300 mg daily),
both, or none (control) for 3.5 years. The primary combined
efficacy endpoint was death, nonfatal myocardial infarction,
and stroke. The baseline lipid profile was as following: serum
TG: 162 mg/dl, HDL: 41.5 mg, LDL: 137 mg/dl and total
cholesterol 211 mg/dl. In this study, n-3 PUFA supplement
reduced primary endpoint by 15% and CV death by 30%.8. Emerging therapies for
hypertriglyceridemia in diabetes
8.1. Dual PPAR a/g agonists
PPAR a agnosits are already available in the market (fibrates)
which reduces serum triglycerides significantly by increasing
activity of lipoprotein lipase. Dual PPAR a/g agonists are
newer agents which reduces serum triglycerides by similarFig. 2 e Physiological actionsmechanism as fibrates, while they also have insulin sensi-
tizing action by PPAR g agonist action. Their overall actions
are summarized in Fig. 2.
As explained earlier, activation of PPAR a results in
increased lipoprotein lipase synthesis and activity in capil-
laries endothelium (causing catabolism of TG in VLDL and
chylomicrons), reduced secretion of VLDL, inhibition of Apo
CIII expression, and increased production of apolipoproteins
Apo AI and Apo AII. The PPAR a/g dual agonists are noted to
reduce triglycerides, raise cardioprotective HDL levels and
improve insulin sensitivity.54
Atmolecular level, PPAR a agonists bind to the lipid binding
domain enabling heterodimerisation with a ligand-activated
retinoid X-receptor (RXR).55 This process triggers a confor-
mational change, leading to the transrepression or trans-
activation of target genes. During transrepression, the
activated PPAR binds to cytokine activated transcription fac-
tors, such as nuclear factor kappa B or activator protein-1.56
Under normal conditions, these transcription factors induce
the synthesis of proteins involved in the inflammatory
response. PPARs can inhibit this process by blocking the
interaction between activated transcription factors and the
promoter region of the target gene, thereby preventing tran-
scription and reducing inflammation. PPAR a agonists have
shown to inhibit the IL-1-stimulated release of IL-6 and in-
flammatory prostaglandins in vascular smoothmuscle cells.57
PPAR g involves in adipocyte proliferation and differenti-
ation and its agonists improve insulin sensitivity by promot-
ing fatty acid storage and inhibiting adipokine synthesis.58
PPAR g is expressed mainly in white and brown adipose tis-
sue, colon, cecum, endothelial cells, vascular smooth muscle
cell (VSMC).59 Several preclinical studies have shown that
PPAR g ligands have pleiotropic effects of preventing cardio-
vascular complications. Agonists of PPAR g possess potent
anti-atherogenic and anti-inflammatory activity by inhibiting
several inflammatory mediators such as TNF, IL-1, IL-6 and
iNOS, and transcription factors such as NFeB, Egr-1 andof dual PPAR agonists.
i n d i a n h e a r t j o u r n a l 6 5 ( 2 0 1 3 ) 6 8 3e6 9 0688AP-1.60 Vascular remodeling, which increases the propensity
of atherosclerosis, has been shown to be negatively regulated
by PPAR g agonists due to inhibition of VSMC growth and
migration.61 Endothelial dysfunction, a major risk factor of
diabetic vascular complications has been noted to be attenu-
ated by PPAR g ligands due to inhibition of vascular inflam-
matory processes.62 Further, PPAR agonists have beneficial
effects in ameliorating hypertension through inhibition of
Rho-kinase activation,63 release of nitric oxide,64 and their
direct calcium channel blocking activity.65
Looking at their mechanism of actions, PPAR dual agonists
appear to be ideal agents for management of ADD as they
reduce insulin resistance (a primary factor in the pathogen-
esis of ADD) and blood glucose levels in addition to hyper-
triglyceridemia. Though many dual PPAR agonists
(muraglitazar, tesaglitazar, etc.) have undergone clinical tri-
als, most have not progressed past Phase III due to unresolved
safety concerns. This may be due to imbalance in proportion
of PPAR a/g agonistic actions of these agents. Changing the
ratio of PPAR a/g agonistic actions of such agents can be a
future research interest for management of ADD. Recently,
one such agent, saroglitazar is approved in India for the
treatment of diabetic dyslipidemia and hypertriglyceridemia
with Type 2 diabetesmellitus not controlled by statin therapy.
In preclinical studies and human clinical trials, saroglitazar
has been found to be exceptionally devoid of conventional
adverse events of typical PPAR a agonist agents (reduced GFR,
increased myopathy with statins and hepatotoxicity) as well
as that of PPAR g agonist agents (pedal edema,weight gain and
congestive heart failure). In phase III studies, saroglitazar also
reduced serum triglycerides significantly and was as effective
as 45 mg/day pioglitazone in reducing glycosylated hemoglo-
bin (HbA1c).669. Microsomal triglyceride transfer protein
(MTTP) inhibitors
The microsomal triglyceride transfer protein (MTP or MTTP)
enzyme is necessary for very low density lipoprotein (VLDL)
assembly and secretion in the liver.67 MTTP is a lipid transfer
protein localized in the endoplasmic reticulum of hepatocytes
and enterocytes, where it initiates the incorporation of lipids
into Apo B, acting as a chaperone to assist in Apo B folding.68
MTTP is necessary for the formation of very low density li-
poprotein (VLDL) particles in hepatocytes and chylomicron
particles in enterocytes. This inhibits the synthesis of chylo-
microns and VLDL. The inhibition of the synthesis of VLDL
leads to reduced levels of plasma LDL-C. ThusMTTP inhibitors
are effective in reducing serum TGs and LDL both at the same
time.
Lomitapide is an MTTP inhibitor which is approved in both
US and The European Union (EU) for management of homo-
zygous familial hypercholesterolemia. In clinical studies of 26
weeks, lomitapide reduced serum TG by 45% and LDL by 50%
in patientswith homozygous familial hypercholesterolemia.69
It can be given once daily in dose 5e60 mg, without food.
Lomitapide was tested in a dose-escalation study in 6 pa-
tients with homozygous FH. All patients were instructed to
follow a low-fat diet and after cessation of all other lipid-lowering therapies for 4 weeks, received lomitapide orally
for 4 weeks. Dose-dependent reductions in LDL-C and TG
levels were observed; those receiving the 1 mg/kg dose effec-
ted a significant 51% and 65% decrease in LDL-C and TG levels,
respectively.67 HDL-C and Apo AI levels did not change
significantlywhile apo B levels decreased by 56% at the 1.0mg/
kg dose.10. DGAT (diacylglycerol acyl transferases)
inhibitors
Diacylglycerol acyl transferases (DGATs) are involved in tri-
glyceride synthesis in adipose tissue, the gut and in the
liver.70 DGAT-2 may be one of the mechanisms by which
niacin reduces hepatic triglyceride and hence VLDL produc-
tion and is expressed in liver and adipose tissue. In contrast,
DGAT-l is expressed in the intestine, liver and adipose tissue
and data from DGAT-l deficient mice and with inhibitors
shows that it is a mechanism that mediates reduction in
triglycerides, hepatic steatosis, obesity and improvement in
insulin resistance.11. Conclusion
Though statins are very useful to reduce CV risk in diabetic
patients, significant morbidity and mortality still remain un-
addressed. Many other risk factors in including ADD can ac-
count for that. Hypertriglyceridemia is a primary abnormality
of ADD in diabetic patients. It is also involved in increased CV
risk in diabetic patients. Currently many different therapies
are available for management of ADD. Newer option like PPAR
dual a/g agonist (e.g. saroglitazar) are keeping a ray of hope
that optimizing the control of ADD will improve CV outcome
of diabetic patients which may help in enhancing morbidity
and mortality benefits in future.Conflicts of interest
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